Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
  • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D223/16—Benzazepines; Hydrogenated benzazepines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• This invention relates to novel substituted 1-benzazapines and derivatives
• compositions comprising such compounds,
• Benzazepine compounds are useful in a number of pharmaceutical
• benzazepines are useful as intermediates for producing pharmaceutically active compounds
• WO 97/24336 discloses a process for the
• Tetrahydro-1 -benzazepines and tetrahydro-l,4-benzodiazepines form the core structure of a
• tetrahydro-1 -benzazepines and tetrahydro-1, 4-benzodiazepines which are reported to be inhibitors of the fibrinogen and vitronectin receptors and useful as inhibitors of platelet
• Bacterial infections are a significant and growing medical problem. They
• Antibiotics are administered both to prevent bacterial infections and to treat
• antibiotics When administered to prevent an infection, antibiotics are
• antibiotics are often chosen.
• Antibiotics work by interfering with a vital bacterial cell function at a specific
• antibiotics include beta-lactams, quinolones,
• Penicillin a member of the beta-lactam class (which also includes extended-spectrum
• the instant invention is directed to novel substituted 1 -benzazepine
• R 1 is H, with the proviso that if R! is H R 4 and R 5 are not both H, substituted or
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted, straight
• R 2 and R 3 cannot both be H;
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl;
• Aa is an amino acid;
• Q is O or S;
• Z is O or S;
• a and b are a single or double bond and when a is a double bond, only R 2 and R 3 are present;
• m is 0, 1 or 2;
• n is 1, 2 or 3; and pharmaceutically acceptable salts or prodrug forms thereof.
• the instant invention is also directed to novel substituted 1 -benzazepine
• R 1 is H, with the proviso that if R! is H R 4 and R 5 are not both H, substituted or
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted,
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl;
• Aa is an amino acid;
• Q is O or S;
• Z is O or S;
• m is 0, 1 or 2; n is 1, 2 or 3; and pharmaceutically acceptable salts or prodrug forms thereof.
• R 2 and R 3 are independently H, halogen
• R ⁇ is
• R 1 is a unsubstituted straight chain
• R 2 is H
• R 3 is (CH2) m CO 2 R
• m 0
• R ⁇ is substituted secondary amine
• R ⁇ is
• QR, Q O, wherein R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic,
• R ⁇ is at
• R 5 is OR where R is H, a substituted or unsubstituted
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl.
• R 1 is H; R 2 and R 3 are independently H,
• halogen substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted,
• R 4 and R 5 cannot both be H; m is 0; Q is O; and Z is O.
• R 1 is alkyl, alkylfluorophenyl, cyano alkyl
• R 5 cannot both be H; and a and b are single bonds.
• R 2 and R 3 are independently H, halogen
• R 1 is H
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or alkynyl, substituted or unsubstituted -Ar or -(CH 2 ) n Ar, substituted or unsubstit
• R 1 is alkyl, alkylfluorophenyl, cyanoalkyl
• R 2 or R 3 is H, halogen, ethyl,
• R 1 is
• R 6 is 3-trifluo romethylbenzylamine, R 2 is H , R 3 is H, R 4 is -NH-SO 2 R 7 , wherein R 7
• R ⁇ is OR where R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar; Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl.
• R 4 is at position 7 and R ⁇ is position 8.
• R! is fluorobenzyl or CH 2 CN and R 3 is H or
• the present invention also provides methods for the treatment of bacterial,
• R 1 is H, substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower
• alkenyl or lower alkynyl or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or
• Aa is an amino acid
• Q is O or S
• Z is O or S
• a and b are each a single or double bond, and when a is a double bond, only R 2 or R 3 is
• n 0, 1 or 2;
• n 1, 2 or 3;
• the present invention also provides methods for the treatment of bacterial,
• R 1 is H, with the proviso if R 1 is H that R 4 and R 5 are not both H, substituted or unsubstituted,
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted,
• R 2 and R 3 can be a
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower
• alkenyl or lower alkynyl or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or
• Aa is an amino acid
• Q is O or S
• Z is O or S
• n 0, 1 or 2;
• n 1, 2 or 3;
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino, benzylamino, 3-
• R 2 is H , R 3 is H, R 4 is -NH-SO 2 R 7 and R 7 is 2-fluorophenyl, R 5 is OR where R is H, a
• Ar is, aryl, arylalkyl
• heterocycle heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl.
• R 4 is at position 7 and R ⁇ is position 8.
• R ⁇ is at position 8
• autoimmune disease in a host in need of such treatment, which method comprises
• the present invention also relates to benzazepines which are useful as vasodilators, vasopressin antagonists, vasopressin agonist, oxytocin antagonist, anti-
• hypertensive agents anti-arrhythmic, anti-fibrillatory, diuretics, platelet aggregation
• inhibitors inhibitors, anti-coagulants, immunomodulatory agent, or agents that promote release of
• R 1 is H, substituted or unsubstituted, straight chain, branched or cyclic, alkyl, alkenyl, or
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower
• alkenyl or lower alkynyl or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or
• Aa is an amino acid
• Q is O or S
• Z is O or S
• a and b are each a single or double bond, and when a is a double bond, only R 2 or R 3 is
• n 0, 1 or 2;
• n 1, 2 or 3;
• central nervous system disorders psychosis, depression, pain, cardiovascular disorders,
• autoimmune disease in a host in need of such treatment, which method comprises
• the present invention also relates to benzazepines which are useful as
• vasodilators vasopressin antagonists, vasopressin agonist, oxytocin antagonist, anti-
• hypertensive agents anti-arrhythmic, anti-f ⁇ brillatory, diuretics, platelet aggregation
• inhibitors inhibitors, anti-coagulants, immunomodulatory agent, or agents that promote release of
• R 1 is H, with the proviso if R 1 is H that R 4 and R 5 are not both H, substituted or unsubstituted,
• R is N,N-dimethylethylenediamino, 2-methoxyethylamino,
• R 2 and R 3 are independently H, halogen, -N 3 , -CN, substituted or unsubstituted,
• R 3 can be a functional group of the following structure:
• R 4 and R 5 are independently H, halogen, -NO 2 , -CN, substituted or unsubstituted, straight
• R 4 and R 5 are independently a functional group of the following structure:
• R is H, a substituted or unsubstituted straight chain, branched or cyclic lower alkyl, lower alkenyl or lower alkynyl, or a substituted or unsubstituted Ar or (CH 2 ) n Ar;
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or
• Aa is an amino acid
• Q is O or S
• Z is O or S
• n 0, 1 or 2;
• n 1, 2 or 3;
• R" is N,N-dimethylethylenediamino, 2-methoxyethylamino, benzylamino, 3-
• R 2 is H
• R 3 is H
• R 4 is -NH-SO 2
• R 7 is 2-fluorophenyl
• R 5 is OR where R is H, a
• Ar is, aryl, arylalkyl, heterocycle, heterocyclic group, heterocyclic, heterocyclyl, or heteroaryl . Also preferred are methods which use compounds of Formula I and Formula II or a pharmaceutically acceptable
• R! is 3 -fluorobenzyl or CH 2 CN and R 3 is H or CO Bu t .
• Another aspect of the invention is directed to processes for making the compounds of the
• alkyl means a branched or unbranched saturated aliphatic
• hydrocarbon radical having the number of carbon atoms specified, or if no number is
• alkyl radicals include methyl, ethyl, n-
• propyl isopropyl, n-butyl, zso-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-
• lower alkyl and “C,-C 6 alkyl” are synonymous and used interchangeably.
• a preferred "C r C 6 alkyl” group is methyl or ethyl.
• alkenyl means a branched or unbranched hydrocarbon radical
• each double bond being independently cis, trans, or a nongeometric isomer.
• alkynyl means a branched or unbranched hydrocarbon radical
• substituted alkyl alkenyl, alkynyl
• Examples of the above substituted alkyl groups include but are not limited to:
• substituted alkyl includes the substituted methyl group
• substituted methyl group examples include groups such as
• alkyloxy or “alkoxy” are used interchangeably herein and denote
• alkylcarbonyl alkanoyl
• acyl alkylcarbonyl
• cycloalkyl refers to a mono-, bi- or tricyclic
• alkyl groups respectively, attached to a sulfur which is in turn the point of attachment of the
• alkythio or substituted alkylthio group to the group or substituent designated.
• heterocyclyl, and heteroaryl generally known to those skilled in organic chemistry and as
• Substituted Ar denotes any substituted, partially saturated
• aromatic, or aromatic, aryl, substituted arylalkyl, and substituted heteroaryl which are
• aryl denotes any mono-, bi- or tricyclic partially saturated aromatic
• hydrocarbon aryl groups include phenyl, napthyl, biphenyl, phenanthrenyl, naphthacenyl and the like (see Lang's Handbook of Chemistry
• substituted phenyl examples include but are not limited to a
• mono- or di(halo)phenyl group such as 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-
• a nitrophenyl group such as 3- or 4-nitrophenyl
• a cyanophenyl group
• substituted phenyl represents disubstituted phenyl groups
• substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro- 4-
• substituted phenyl groups include the 2- and 3-trifluoromethylphenyl, the 4-hydroxyphenyl, the 2-aminomefhylphenyl
• arylalkyl means one, two or three aryl groups having 3 to 14
• substituted arylalkyl denotes an alkyl group substituted at any
• the aryl group may be substituted with one, two or three groups chosen from
• substituted arylalkyl examples include groups such as 2-phenyl-
• heterocycle Unless otherwise specified, the terms “heterocycle”, “heterocyclic group”,
• heterocyclic or “heterocyclyl” are used interchangeably herein and includes any mono-, bi-
• the heterocycle is a 5-, 6- or 7-member saturated, unsaturated or
• aromatic hydrocarbon ring containing 1, 2, or 3 heteroatoms selected from O, N and S.
• the 5-membered ring has 0 to 2 double bonds and the 6- or 7-membered ring has 0
• nitrogen heteroatom may optionally be quarternized. Included in the definition are any
• bicyclic groups where any of the above heterocyclic rings are fused to a benzene ring.
• Heterocyclics in which nitrogen is the heteroatom are preferred.
• the following ring systems are examples of the heterocyclic (whether
• heterocyclic thienyl, furyl,
• thiadiazolyl oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl,
• oxathiazinyl tetrazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, dihydropyrimidyl, tetrahydropyrimidyl, tetrazolo-(l, 5b)-pyridazinyl and purinyl, as well as benzo-fused
• one to three nitrogen atoms are also suitable for use in the instant invention. Examples of
• Such preferred groups included thiazolyl in particular thiazol-2-yl and thiazol-2-yl N-oxide,
• thiadiazolyl in particular l,3,4-thiadiazol-5-yl and l,2,4-thiadiazol-5-yl, oxazolyl, preferably
• oxazol-2-yl oxazol-2-yl
• oxadiazolyl such as l,3,4-oxadiazol-5-yl, and l,2,4-oxadiazol-5-yl.
• imidazolyl preferably imidazol-2-yl
• triazolyl preferably l,3,4-triazol-5-yl
• benzo-fused derivatives examples are benzoxazol-2-yl, benzthiazol-2-yl and
• pyridyl such as pyrid-2-yl, pyrid-3-yl, and pyrid-4-yl
• pyrimidyl preferably pyrimid-2-yl
• pyrimid-4-yl triazinyl, preferably l,3,4-triazin-2-yl and l,3,5-triazin-4-yl; pyridazinyl, in
• pyridyl, pyrimid-2-yl, pyrimid-4-yl, pyridazinyl and the l,3,4-triazin-2-yl radicals are a
• preferred 6-membered ring heterocycles are: piperazinyl,
• piperazin-2-yl piperidyl, piperid-2-yl, piperid-3-yl, piperid-4-yl, mo ⁇ holino, mo ⁇ holin-2-yl
• heterocyclics include: l,3-thiazol-2-yl, 4-
• heterocyclics includes: 4-(carboxymethyl)-5-methyl-
• heteroaryl group or “heteroaryl” are used interchangeably herein
• heteroaryl refers to aromaticity, a
• Typical natural amino acids include but
• alanine is not limited to alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic
• amino acid of Aa include, but are not limited
• trityl-cysteine glutamic acid, glutamic acid- ⁇ -t-butyl ester, glutamine, N- ⁇ -trityl-glutamine,
• glycine histidine, N ⁇ m -trityl-histidine, isoleucine, leucine, lysine, N ⁇ -Boc-lysine,
• norvaline L-2-amino-4-pentenoic acid, D-isoleucine, L-isoleucine, D-norleucine, 2,3-
• aminovaleric acid 5-aminocaproic acid, 7-aminoheptanoic acid, 8-aminocaprylic acid, 11-
• aminodecanoic acid 12-aminododecanoic acid, carboxymethoxylamine, D-serine, D-
• homoserine L-homoserine, D-allothreonine, L-allothreonine, D-threonine, L-threonine, D,L-
• proline cis-4-hydroxy-L-proline, trans-4-hydroxy-L-proline, 3,4-dehydro-D,L-proline, 3,4- dehydro-L-proline, D-pipecolinic acid, L-pipecolinic acid, nipecotic acid, isonipecotic acid,
• aminoadipic acid (+/-)-3-aminoadipic acid, D-cysteine, D-penicillamine, L-penicillamine,
• D,L-homocysteine S-methyl-L-cysteine, L-methionine, D-ethionine, L-ethionine, S-
• chlorophenylalanine 4-bromo-D,L-phenylalanine, 4-iodo-D-phenylalanine, 3,3',5-triiodo-L-
• phenylalnine 4-amino-D,L-phenylalanine, 4-nitro-L-phenylalanine, 4-nitro-D,L-
• NH 2 NH 2 moiety, and includes but is not limited to alkyl-amines, alkenyl-amines, alkynyl-
• Examples of primary amines include, but are not limited to any of those listed
• tryptamine 5 -fluoro-1- tryptophan, 5-fluoro-d,l,-tryptophan, 4-(trifluoromethyl)aniline, 4-
• secondary amines include, but are not limited to any of those
• nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or
• compositions which retain the
• nitric acid nitric acid, phosphoric acid and the like
• organic acids such as acetic acid, propionic acid,
• glycolic acid pyruvic acid, oxalic acid, maleic acid, maloneic acid, succinic acid, fumaric
• inorganic bases such as sodium, potasium, lithium, ammonium, calcium, magnesium, iron,
• pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary and
• tertiary amines substituted amines including naturally occurring substituted amines, cyclic
• amines and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine,
• dicyclohexylamine dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine,
• non-toxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine,
• Prodrugs are considered to be any covalently bonded carriers which release
• Prodrugs include, but are not limited to, compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when
• prodrugs include, but are not limited to, acetate, formate and
• stable compound or “stable structure” is meant herein a compound that is
• carboxylic acid protecting groups examples include 4-nitrobenzyl, 4-
• acid protecting groups are the allyl, tert-butyl and p-nitrobenzyl groups. Similar carboxy-
• amino-protecting group refers to any group
• Such groups include 3,4-dimethoxybenzyl, benzyl, p-nitrobenzyl, di-(p-
• substituted ⁇ -tetralones 1 to benzo-fused lactams 3 can be achieved by a number of methods
• oxime 2 that may be isolated or used as is.
• Suitable methods for transformation 1 to 3 involve the use of the Beckmann Rearrangement
• electrophilic reagents can capture an anion, formed on ⁇ -position relative to amide
• the intermediate 4 may be again reacted with an inert base in an
• bases may include, but are not
• alkylating reagents would include, but are not
• acetonitrile would include, but are not limited to acetonitrile, acetone, DMA, DMF and the like.
• bromination reagents would include, but are not limited to N-
• bromosuccinimide N-bromosuccinimide + co-reagent, N-bromoacetamide, bromine, bromine
• alkyl/aryl amines would also displace Br, CI and I leaving groups.
• intermediate 6 is displaced preferentially using a nucleophilic amine such as piperazine,
• Co-bases such as K 2 CO 3 , Cs 2 CO 3 , NaOBu', KOBu', K 3 PO 4 and the like are usually used to prepare Co-bases.
• R 4 Y represents a compound wherein R 4 is defined according to the invention and Y is a leaving group that allows R 4 to be inserted into the ring.
• Y includes but is not limited to -SnBu 3 (tributyl tin), Sn(CH 3 ) 3 and -B(OH) 2 .
• heteroaryls may also be introduced at X on the benzo-fused lactams ring when X is Br, I, CI
• starting compound 8 could be chosen from an array of groups or precursors thereof indicated
• lactam is a methoxy group it can be deprotected using BBr 3 , BI 3 , A1I 3 , A1C1 3 , A1C1 3 +NaSEt,
• the dimethyl tert-butyl silyl protecting group of the intermediate 12 may be removed by
• GENERAL SCHEME C 14 An alkylation of 13 can be carried out with inert bases such as K 2 CO 3 , Cs 2 CO 3 ,
• Solvents are typically, but are not limited to dioxane, DMF, DMA, and
• reagents in the latter cases are limited to alkyl and substituted benzyl iodides and bromides.
• phenylboronic acids are also efficient arylating agents and the relevant reaction represents a
• the reaction can be performed under very mild conditions
• reaction conditions i. e. room temperature and with an amine base.
• triarylbismuth represent an attractive alterantive in O-arylations since a large number of
• organo boronic acids are either commercially available or their syntheses are well described
• the phenol type derivative 13 of substituted l-benzazepine-2-one can be
• the intermediate 15 can be subjected to a coupling reaction with
• organotin reagents and organoboronates may be used with palladium catalysts to
• anilines can be further acylated using any 3-chloro 3-oxopropionate (alkyl/benzyl malonyl
• Solvents would typically include THF, ether, 1,4
• a cyclization of 20 can be achieved by a number of methods well known in

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Rheumatology (AREA)
• Biomedical Technology (AREA)
• Physical Education & Sports Medicine (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Dermatology (AREA)
• Psychiatry (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Oncology (AREA)
• Urology & Nephrology (AREA)
• Communicable Diseases (AREA)
• Vascular Medicine (AREA)
• Tropical Medicine & Parasitology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23118365

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (9)

Family Cites Families (7)

• 2002
  • 2002-05-15 WO PCT/US2002/015214 patent/WO2002100327A2/en not_active Ceased
  • 2002-05-15 EP EP02763196A patent/EP1392317A4/en not_active Withdrawn
  • 2002-05-15 US US10/477,595 patent/US20050234041A1/en not_active Abandoned
  • 2002-05-15 AU AU2002327172A patent/AU2002327172B2/en not_active Expired - Fee Related
  • 2002-05-15 CA CA002447687A patent/CA2447687A1/en not_active Abandoned
  • 2002-05-15 JP JP2003503154A patent/JP2004536079A/ja active Pending

Also Published As

Similar Documents

Legal Events